Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas
| Autor: | Deok-Joo Rhee, Sang Young Song, Kwan Park, Sung Tae Kim, Do-Hoon Lim, Kwon-Byong Park, Jong Hyun Kim, Jung-Il Lee, Do-Hyun Nam, Won Seog Kim, Doo-Sik Kong, Yeon-Lim Suh |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male medicine.medical_specialty Nitrosourea Adolescent medicine.medical_treatment Neurosurgical Procedures Nitrosourea Compounds Central nervous system disease Cohort Studies chemistry.chemical_compound Young Adult medicine Temozolomide Humans Child Antineoplastic Agents Alkylating Aged Retrospective Studies Chemotherapy business.industry Brain Neoplasms Cancer General Medicine Middle Aged medicine.disease Combined Modality Therapy Magnetic Resonance Imaging Survival Analysis Surgery Radiation therapy Dacarbazine chemistry Chemotherapy Adjuvant Case-Control Studies Child Preschool Cohort Female Neurology (clinical) business Glioblastoma Adjuvant medicine.drug Follow-Up Studies |
| Zdroj: | Clinical neurology and neurosurgery. 111(9) |
| ISSN: | 1872-6968 |
| Popis: | Objectives The aim of this study was to assess the efficacy of adjuvant TMZ chemotherapy for newly diagnosed GBM patients who were treated with surgery followed by radiotherapy alone. Material and methods Between January 2003 and April 2005, 59 consecutive GBM patients underwent radiation therapy after surgical resection and subsequently received TMZ chemotherapy. For the comparative analysis, we selected 60 clinically matched GBM patients who underwent radiotherapy followed by nitrosourea-based chemotherapy (NUBC), at the same institution between June 1995 and April 2005. The study cohort was divided into two groups, those with adjuvant TMZ treatment and with NUBC. Results 59 patients with adjuvant TMZ treatment were assigned to the treatment group and 60 patients with NUBC to the control group. The median overall survival for the treatment group was 18.2 months (95% CI, 11.7–24.7 months), compared with the survival of 14.5 months (95% CI, 11.2–17.7 months) for the control group ( p =0.019). The progression-free survival for the treatment group was 5.6 months (95% CI, 4.4–6.7 months), while the control group showed progression-free survival of 3.3 months (95% CT, 3.2–6.0 months) ( p =0.030). Uni- and multivariate analysis revealed that extent of surgical resection, age ≥55 years and postoperative KPS were significantly associated with survival. Conclusion Adjuvant TMZ chemotherapy provided a clinically relevant benefit of survival, as compared with NUBC. Thus, we suggest that adjuvant TMZ chemotherapy may be effective even for patients who did not receive concomitant chemoradiotherapy for GBM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect